Balance and mobility in patients with newly diagnosed Parkinson's disease - a five-year follow-up of a cohort in northern Sweden.

Johansson C, Lindström B, Forsgren L, Johansson GM.

Disabil Rehabil. 2020 Mar;42(6):770-778. doi: 10.1080/09638288.2018.1509240. Epub 2018 Nov 19.

Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.

Zenchak JR, Palmateer B, Dorka N, Brown TM, Wagner LM, Medendorp WE, Petersen ED, Prakash M, Hochgeschwender U.

J Neurosci Res. 2020 Mar;98(3):458-468. doi: 10.1002/jnr.24237. Epub 2018 Mar 25.

Executive function but not episodic memory decline associated with visual hallucinations in Parkinson's disease.

Creese B, Albertyn CP, Dworkin S, Thomas RS, Wan YM, Ballard C.

J Neuropsychol. 2020 Mar;14(1):85-97. doi: 10.1111/jnp.12169. Epub 2018 Jul 23.

A Survey of Application of Complementary and Alternative Medicine in Chinese Patients with Parkinson's Disease: A Pilot Study.

Pan XW, Zhang XG, Chen XC, Lu Q, Hu YS, Han LY, Zheng JL, Jin J, Zheng GQ.

Chin J Integr Med. 2020 Mar;26(3):168-173. doi: 10.1007/s11655-018-2560-y. Epub 2018 Jun 18.

A sticky situation: Aberrant protein-protein interactions in Parkinson's disease.

Brown J, Horrocks MH.

Semin Cell Dev Biol. 2020 Mar;99:65-77. doi: 10.1016/j.semcdb.2018.05.006. Epub 2018 May 10. Review.

Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.

Dodiya HB, Forsyth CB, Voigt RM, Engen PA, Patel J, Shaikh M, Green SJ, Naqib A, Roy A, Kordower JH, Pahan K, Shannon KM, Keshavarzian A.

Neurobiol Dis. 2020 Feb;135:104352. doi: 10.1016/j.nbd.2018.12.012. Epub 2018 Dec 21. Review.

Neuropsychiatric complications and neuroimaging characteristics after deep brain stimulation surgery for Parkinson's disease.

Radziunas A, Deltuva VP, Tamasauskas A, Gleizniene R, Pranckeviciene A, Surkiene D, Bunevicius A.

Brain Imaging Behav. 2020 Feb;14(1):62-71. doi: 10.1007/s11682-018-9971-4.

Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges.

Martin-Rodriguez JF, Mir P.

Neurosci Lett. 2020 Feb 6;719:133679. doi: 10.1016/j.neulet.2018.06.048. Epub 2018 Jun 28. Review.

Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction.

Suda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y, Iwasawa C, Shibasaki M, Maekawa A, Matsuo M, Akamatsu W, Hattori N, Okano H, Narita M.

Mol Brain. 2018 Feb 20;11(1):6. doi: 10.1186/s13041-018-0349-8.

miR-494-3p modulates the progression of in vitro and in vivo Parkinson's disease models by targeting SIRT3.

Geng L, Zhang T, Liu W, Chen Y.

Neurosci Lett. 2018 Mar 19;675:23-30. doi: 10.1016/j.neulet.2018.03.037. [Epub ahead of print]

Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.

Houvenaghel JF, Drapier S, Duprez J, Robert GH, Riou A, Drapier D, Sauleau P, Vérin M.

J Neurol Sci. 2018 Oct 7;395:113-118. doi: 10.1016/j.jns.2018.10.010. [Epub ahead of print]

Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson's disease.

Dong Y, Han LL, Xu ZX.

Mol Med. 2018 Nov 28;24(1):61. doi: 10.1186/s10020-018-0059-9.

Comparative analysis of Parkinson's disease-associated genes reveals altered survival and bioenergetics of parkin-deficient dopamine neurons in mice.

Giguere N, Pacelli C, Saumure C, Bourque MJ, Matheoud D, Levesque D, Slack RS, Park DS, Trudeau LE.

J Biol Chem. 2018 Apr 26. pii: jbc.RA117.000499. doi: 10.1074/jbc.RA117.000499. [Epub ahead of print]

Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease.

Müller T, Kohlhepp W.

Med Hypotheses. 2018 Jan;110:46-49. doi: 10.1016/j.mehy.2017.10.030. Epub 2017 Oct 31.

[The gut microbiome in Parkinson disease].

Bedarf JR, Hildebrand F, Goeser F, Bork P, Wüllner U.

Nervenarzt. 2018 Aug 31. doi: 10.1007/s00115-018-0601-6. [Epub ahead of print] Review. German.